Psilocybin and Rabies Virus Combination Maps Brain Rewiring, Offering New Hope for Depression Treatment
Table of Contents
A groundbreaking international study has revealed how psilocybin, teh active compound in magic mushrooms, reshapes brain circuits, potentially unlocking new avenues for treating depression.Researchers at Cornell University, in collaboration with the Allen Institute for Brain Science, employed a novel approach – combining psilocybin with a modified rabies virus – to map the intricate changes occurring within the brain under the influence of the psychedelic compound.
Prior research established that psilocybin could induce lasting changes in brain structure, specifically by promoting the growth of dendritic spines – the connections between neurons. Though, a key question remained: where exactly were these new connections forming? To address this, the research team adopted an innovative strategy. Instead of relying solely on optical imaging, they utilized a genetically engineered rabies virus to trace the newly formed neural pathways.
“With psilocybin, it’s like we’re adding all these roads to the brain, but we don’t know where the roads go,” explained a senior researcher involved in the study. “Here we use the rabies virus to read out the connectivity in the brain, as these viruses are engineered in nature to transmit between neurons.” The virus acts as a tracer, moving along the newly established connections and labeling them with fluorescent proteins, allowing researchers to visualize the brain’s “very complex wiring diagram.”
Key Findings: Breaking Negative Thought Cycles
The study involved injecting a single dose of psilocybin into the frontal cortical pyramidal neurons of mice, followed by the rabies virus. After a week of incubation, brain imaging revealed significant changes in neural connectivity.Specifically, the researchers found that psilocybin weakened recurrent connections within the cortex – feedback loops frequently enough associated with rumination and negative thinking.
“Rumination is one of the main points for depression, where people have this unhealthy focus and they keep dwelling on the same negative thoughts,” a lead researcher stated. “By reducing some of these feedback loops, our findings are consistent with the interpretation that psilocybin may rewire the brain to break, or at least weaken, that cycle.”
Furthermore, the study showed that psilocybin strengthened the connection between the sensory areas of the brain and subcortical regions, enhancing the link between perception and action. This suggests a potential mechanism for psilocybin’s ability to improve sensory-motor responses.
Implications for Future Therapeutic Growth
Initially, researchers anticipated observing rewiring in only a few specific brain regions. Though, the study revealed a far more extensive, brain-wide reorganization. “This is really looking at brain-wide changes,” noted a senior author of the study. “That’s a scale that we have not worked at before.”
Perhaps even more considerably,the team discovered that the level of neural activity within a brain region influences how psilocybin rewires the circuitry.by manipulating neural activity, they were able to alter the drug’s effects on brain connections.
“That opens up many possibilities for therapeutics, how you maybe avoid some of the plasticity that’s negative and then enhance specifically those that are positive,” the researcher explained. This suggests a future where psilocybin-based treatments could be tailored to individual patients, maximizing therapeutic benefits while minimizing potential side effects.
This research represents a significant step forward in understanding the neurological basis of psilocybin’s antidepressant effects. While further investigation is needed, these findings offer a promising path toward developing more effective and targeted treatments for depression and other mental health conditions.
more data: Quan Jiang et al,Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks,Cell (2025). DOI: 10.1016/j.cell.2025.11.009
Journal information: Cell
Provided by
Cornell University
